miR-425-5p Inhibits Rat Mesangial Cells (MCs) Proliferation by Targeting Transforming Growth Factor Beta (TGF-β)/RelA (p65) Under the Condition of Sitagliptin

Author:

Li Xia,Liu Yilan,Zhang Yi,Hong Zhenzhen

Abstract

Objective: Sitagliptin (Sitagtin) is widely involved in the treating process for several diseases in humans, covering DN (Diabetic Nephropathy). In the present research, the aim was at examining the roles of the miR-425-5p/TGFβ /P65 pathway in a DN rat model treated by Sitagtin. Methods: The subjects fed high-fat food were killed. Besides, new kidney specimens were placed in formaldehyde solution for histopathology-based observing process. Subsequently, Coomassie brilliant blue approach was used to determine urine protein excretion for 24 hours. Lastly, by bicinchoninic acid protein assay, proteins harvested from kidney tissue were detected. Results: Firstly, it was identified that miR-425-5p showed the highest expression in Sitagtin treatment cells compared to PBS treatment through miRNA microarray analysis. In addition, Sitagtin suppressed the HBZY-1 cell lines' proliferation, which may inhibit TGFβ /P65 expression through upregulating miR-425-5p. Furthermore, after HBZY-1 cells induced by high glucose (HG) were administrated with Sitagtin, miR-425-5p and si TGF /P65 inhibited HBZY-1 cells from proliferating. It was proved that TGFβ /P65 was one of the targeted genes of miR-425-5p. Lastly, TGFβ /P65 expression was decreased in the DN administrated with Sitagtin; the 24 h urinary protein excretion was decreased in Sitagtin-administrated DN rats. Conclusion: The study demonstrated that Sitagtin inhibited HBZY 1 cells through miR-4255p/TGFβ /P65 signaling.

Publisher

American Scientific Publishers

Subject

Biomedical Engineering,Medicine (miscellaneous),Bioengineering,Biotechnology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3